Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4642449 | 0.71 | NR1H2 (0.32) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL5569284 | 0.71 | NR1H2 (0.40) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL1049841 | 0.67 | ALDH1A1 (0.41) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL1051334 | 0.67 | ALDH1A1 (0.41) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL1053231 | 0.67 | ALDH1A1 (0.41) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL14777395 | 0.67 | ESR1 (0.32) | NR1H2NR1H3ALDH1A1ESR1ESR2 | |
| SCHEMBL705989 | 0.66 | ESR1 (0.40) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL703156 | 0.66 | ESR1 (0.40) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL15091606 | 0.64 | NR1H2 (0.33) | NR1H2NR1H3ALDH1A1TSHRESR1 | |
| SCHEMBL23701389 | 0.64 | ALDH1A1 (0.38) | NR1H2NR1H3ALDH1A1TSHRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163046-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20100113717-A1 | Process For Producing Substituted Metallocene Compounds For Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2010-05-06 | — | — | US | disclosed |
| US-7709670-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1866322-B1 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1866322-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006065844-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113717-A1 | Process For Producing Substituted Metallocene Compounds For Olefin Polymerization | OSBP, OSBPL3, OSBP2 | NR1H2 160/4885NR1H3 112/4885ALDH1A1 2387/4885 |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | OSBP, OSBPL3, OSBP2 | NR1H2 160/4885NR1H3 112/4885ALDH1A1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.